It is expected to treat squamous cell carcinoma of the head and neck. The anti-PD-1 antibody of mosadon has won the positive evaluation of the European Drug Commission
-
Last Update: 2019-10-19
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
MSD today announced that the European Drug Administration's Committee on human medicinal products (CHMP) recommended approval of two options of keytruda (anti PD-1 therapy of MSD) for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) For patients with tumor expression of PD-L1 (with positive score [CPS] ≥ 1), keytruda is recommended as a single therapy or combined with platinum and 5-fluorouracil (5-FU) chemotherapy This recommendation is based on key phase 3 keynote-048 trial data, in which keytruda as a combination of monotherapy and chemotherapy compared to standard therapy (cetuximab plus carboplatin or cisplatin plus 5-FU) showed a significant improvement in overall survival in the corresponding patient population MSD currently has the largest clinical development program for head and neck squamous cell carcinoma, and is continuing to promote a variety of registered support studies Keytruda is planned to be studied as a monotherapy and in combination with other cancer therapies, including keynote-412 and keynote-689 The CHMP proposal will now be reviewed by the European Commission to obtain marketing permission from the EU The final decision will be made in the fourth quarter of 2019 (Bio Valley / bio on Com) original source: moshadong official website
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
